Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 43,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
52% more first-time investments, than exits
New positions opened: 243 | Existing positions closed: 160
12% more repeat investments, than reductions
Existing positions increased: 1,528 | Existing positions reduced: 1,369
2% more funds holding
Funds holding: 3,494 [Q2] → 3,577 (+83) [Q3]
1.67% less ownership
Funds ownership: 83.63% [Q2] → 81.96% (-1.67%) [Q3]
6% less capital invested
Capital invested by funds: $719B [Q2] → $677B (-$41.8B) [Q3]
12% less call options, than puts
Call options by funds: $9.13B | Put options by funds: $10.4B
15% less funds holding in top 10
Funds holding in top 10: 542 [Q2] → 460 (-82) [Q3]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$975
27%
upside
Avg. target
$1,059
38%
upside
High target
$1,250
63%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 30%upside $997 | Buy Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 30%upside $1,000 | Outperform Initiated | 15 Nov 2024 |
Deutsche Bank James Shin 0% 1-year accuracy 0 / 4 met price target | 32%upside $1,015 | Buy Maintained | 4 Nov 2024 |
Barclays Carter Gould 30% 1-year accuracy 11 / 37 met price target | 27%upside $975 | Overweight Maintained | 31 Oct 2024 |
B of A Securities Geoff Meacham 28% 1-year accuracy 7 / 25 met price target | 43%upside $1,100 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 120 articles about LLY published over the past 30 days
Positive
The Motley Fool
4 hours ago
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts. Furthermore, the pursuit of dividends need not come at the expense of other investment styles.
Neutral
The Motley Fool
8 hours ago
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (LLY 1.35%) reported earnings for the third quarter on Oct. 30, shares have been punished by investors. As of this writing, Lilly's stock price has plunged as much as 14% since Q3 earnings, and it's currently trading 6% lower than it was prior to the report.
Positive
Investors Business Daily
19 hours ago
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. The post Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Positive
Forbes
19 hours ago
Zepbound Approved For Sleep Apnea
The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound approved as a weight-loss drug last year.
Positive
Reuters
20 hours ago
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
Positive
CNBC
20 hours ago
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted during sleep due to narrowed or blocked airways.
Neutral
PRNewsWire
20 hours ago
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity.
Neutral
CNBC Television
23 hours ago
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Positive
Seeking Alpha
1 day ago
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the results from the head-to-head showing superiority trial to Novo Nordisk's semaglutide. With CagriSema underperforming expectations this week, the risk of a product superior to tirzepatide coming to market in the next few years is greatly reduced.
Negative
Zacks Investment Research
1 day ago
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
Charts implemented using Lightweight Charts™